explore -WSS

explore

author：focus 2025-09-29 09:55:00 - browse：7

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Medicaid rebukes states for mistakenly disenrolling children

hotspot

WSS

Humana sues Biden admin over Medicare Advantage audit rule

Radiation, mainstay of cancer treatment, begins a fade

What American doctors can learn from their Israeli counterparts

The 10 drugs up first for Medicare price negotiation

Trump surgeon general acknowledges mistakes during Covid

Weighted lottery helped low

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Humana sues Biden admin over Medicare Advantage audit rule

United colonoscopy coverage change 'may cost lives,' doctors say

Study finds new variant for Parkinson’s in African populations

Apple is now the first public company to be valued at $3 trillion

Winners, losers from Medicare’s list of drugs subject to price talks

New air purifier tech could be key to improving indoor air quality

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Dobbs anniversary: the lost opportunity of abortion as health care

In science, is the line between industry and academia shifting?

explore

ALS advocates say criticism of new drugs misses bigger picture

How to protect patients from sexual assault

Humana sues Biden admin over Medicare Advantage audit rule

FDA panel gives mixed vote on blood pressure devices

The (many) problems with a new study criticizing cancer screening

Illumina names Agilent executive as new CEO

entertainment

entertainment

hotspot

knowledge